20,000 Shares in Boston Scientific Co. (NYSE:BSX) Bought by Generali Investments CEE investicni spolecnost a.s.

Generali Investments CEE investicni spolecnost a.s. acquired a new position in shares of Boston Scientific Co. (NYSE:BSX) in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor acquired 20,000 shares of the medical equipment provider’s stock, valued at approximately $1,786,000.

A number of other large investors have also recently bought and sold shares of BSX. Van ECK Associates Corp raised its position in Boston Scientific by 18.1% during the third quarter. Van ECK Associates Corp now owns 57,894 shares of the medical equipment provider’s stock valued at $5,063,000 after purchasing an additional 8,882 shares in the last quarter. Impax Asset Management Group plc lifted its position in shares of Boston Scientific by 17.5% during the 3rd quarter. Impax Asset Management Group plc now owns 5,470,174 shares of the medical equipment provider’s stock worth $457,138,000 after buying an additional 815,403 shares during the last quarter. Concurrent Investment Advisors LLC boosted its stake in Boston Scientific by 5.8% in the third quarter. Concurrent Investment Advisors LLC now owns 9,724 shares of the medical equipment provider’s stock valued at $815,000 after buying an additional 530 shares in the last quarter. M&G PLC bought a new position in Boston Scientific in the third quarter valued at about $1,327,000. Finally, Capital Performance Advisors LLP acquired a new position in Boston Scientific during the third quarter worth about $30,000. 89.07% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

BSX has been the topic of several research reports. Deutsche Bank Aktiengesellschaft raised shares of Boston Scientific from a “hold” rating to a “buy” rating and set a $108.00 price target on the stock in a report on Friday, January 10th. Wells Fargo & Company boosted their target price on shares of Boston Scientific from $100.00 to $118.00 and gave the stock an “overweight” rating in a research note on Thursday, February 6th. UBS Group increased their price target on Boston Scientific from $105.00 to $130.00 and gave the company a “buy” rating in a research note on Friday, February 7th. Piper Sandler boosted their price objective on Boston Scientific from $95.00 to $115.00 and gave the stock an “overweight” rating in a research report on Monday, February 3rd. Finally, Argus set a $130.00 target price on Boston Scientific in a research report on Tuesday, February 18th. Two investment analysts have rated the stock with a hold rating, twenty-one have issued a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $108.91.

Boston Scientific Trading Down 1.6 %

Shares of BSX stock opened at $99.15 on Friday. Boston Scientific Co. has a fifty-two week low of $65.52 and a fifty-two week high of $107.17. The company has a debt-to-equity ratio of 0.41, a quick ratio of 1.02 and a current ratio of 1.08. The stock has a 50 day simple moving average of $100.45 and a two-hundred day simple moving average of $91.19. The company has a market cap of $146.33 billion, a P/E ratio of 79.32, a PEG ratio of 2.79 and a beta of 0.77.

Boston Scientific (NYSE:BSX) last released its quarterly earnings data on Wednesday, February 5th. The medical equipment provider reported $0.70 earnings per share for the quarter, beating the consensus estimate of $0.65 by $0.05. Boston Scientific had a net margin of 11.07% and a return on equity of 17.80%. Research analysts forecast that Boston Scientific Co. will post 2.85 earnings per share for the current year.

Insider Activity

In other news, CFO Daniel J. Brennan sold 15,087 shares of the business’s stock in a transaction that occurred on Wednesday, February 12th. The stock was sold at an average price of $105.07, for a total transaction of $1,585,191.09. Following the completion of the sale, the chief financial officer now owns 241,451 shares in the company, valued at $25,369,256.57. The trade was a 5.88 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, EVP John Bradley Sorenson sold 1,201 shares of the stock in a transaction on Friday, February 14th. The stock was sold at an average price of $106.31, for a total value of $127,678.31. Following the completion of the transaction, the executive vice president now owns 25,443 shares in the company, valued at approximately $2,704,845.33. This represents a 4.51 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 137,322 shares of company stock worth $14,321,068. Company insiders own 0.50% of the company’s stock.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.